GC Cell Presents CAR-NK Therapy Research Results at American Association for Cancer Research Conference

GC Cell, a cell therapy development subsidiary of GC Green Cross, announced on the 11th that it presented a poster on the preclinical study results of GL205/GCC2005, a CD5 chimeric antigen receptor (CAR)-natural killer (NK) therapy, and real-world data (RWD) of the anticancer immune cell therapy Imucell-LC at the American Association for Cancer Research (AACR).

Josungrim, head of the GC Cell Discovery Team, is explaining a poster at the AACR event.
[Photo by GC Cell]

GCC2005 is a new modality that equips allogeneic umbilical cord blood-derived NK cells with a CAR targeting CD5, which is expressed in T-cell lymphoma. It was explained that the previously limited application range, due to various subtypes of T-cell lymphoma and low expression of CD30, has been expanded to a broader patient population by targeting CD5.

The AACR presentation included content showing that GC Cell’s proprietary technology of CAR and interleukin (IL)-15 co-expression significantly improved the short persistence, which was a limitation of conventional NK cells. Through this, it demonstrated the potential of GCC2005 as an innovative new drug for T-cell lymphoma based on its excellent cancer cell killing ability and improved in vivo persistence.

The research presentation led by Professor Choi Jong-geon’s team from Konyang University Hospital’s Department of Hematology and Oncology revealed study results on the combination therapy of Imucell-LC with already approved targeted therapies or immune checkpoint inhibitors. In this study, Imucell-LC showed meaningful clinical improvements through combination cases with immune checkpoint inhibitors.